Clinical trials: Mutation Burden
Predictive Cancer Model
Innovative Approach to Detect Recurrent Colorectal Lesions With Surveillance Via Mutation Analysis & Clinical Phenotype
It is known that the development of colorectal adenoma is dependent on the appearance of somatic mutations in protooncogenes and tumor suppressor genes.
- Trial name
- MTG (NCT05929365)
- Testing
- colonoscopy
- Where
- Czechia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Military University Hospital, Prague
Osteosarcoma
Cancer Genome Study Using Samples From Patients Treated on Clinical Trial SHR1020-SHR-1210-II-OS
RATIONALE: Studying samples of tumor tissue from patients with advanced osteosarcoma refractory to chemotherapy in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to…
- Trial name
- CSSG-02 (NCT03997747)
- Testing
- cytology specimen
- Where
- 2 sites in China
- Volunteers
- 38 people
- Sponsor
- Peking University People's Hospital
Polycythemia Vera, ET (Essential Thrombocythemia)
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
The MPN PROGRESSion Registry is a multi-year, observational research study designed to improve understanding of myeloproliferative neoplasms (MPNs)-a group of rare, chronic blood cancers that include polycythemia vera (PV)…
- Conditions
- Polycythemia Vera, ET (Essential Thrombocythemia), Polycythemia Vera (PV), Essential Thrombocythemia (ET)
- Trial name
- NCT07362225
- Where
- 2 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- MPN Research Foundation
Parkinson Disease
Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease
The project intends to assess the polygenic burden of rare disruptive mutations in Parkinson's disease (PD) and how they influence the phenotype/pathological heterogeneity of disease.
- Trial name
- NCT04620980
- Testing
- targeted resequencing
- Where
- Italy
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Neuromed IRCCS
Ovarian Neoplasms, Fallopian Tube Neoplasms
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
Niraparib is an oral, potent and highly selective PARP1/2 inhibitor. It can be used as a single drug in HRD positive ovarian cancer patients for multi-line therapy.
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Endocrine Gland Neoplasms, Neoplasms by Site
- Trial name
- AVANIRA3 (NCT04556071)
- Testing
- Niraparib, Bevacizumab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Xiaoxiang Chen
Pancreatic Cancer
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with high tumour mutation burden
- Trial name
- NCT05093231
- Testing
- Pembrolizumab, Olaparib
- Where
- 17 sites in Australia, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Resectable Pancreatic Ductal Adenocarcinoma
Nalirinox Neo-pancreas RAS Mut ctDNA Study
Pancreatic cancer has an unfavorable prognosis with a reduced possibility of long-term survival. The only treatment with curative potential is surgery, but it is only possible in 15-20% of cases.
- Trial name
- NCT04010552
- Testing
- NALRINOX combination
- Where
- 3 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Fundación de investigación HM
Atherosclerosis
Arterial Function and Atherosclerosis in Essential Thrombocythemia
The aim of the study is to examine (a) whether patients with JAK2 V617F positive ET in comparison to age-and sex-matched, apparently healthy control subjects show more advanced progression of arterial stiffness, pulse-wave…
- Trial name
- NCT03828422
- Testing
- imaging
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- University Medical Centre Ljubljana
Solid Tumor
A MolEcularly Guided Anti-Cancer Drug Off-Label Trial
This is a prospective, open-label, non-randomized combined basket- and umbrella trial divided in two parts; a limited feasibility-oriented part 1 including 154 patients and 3 treatment cohorts and part 2 that will include an…
- Trial name
- MEGALiT (NCT04185831)
- Testing
- Atezolizumab, Everolimus, Cobimetinib
- Where
- 3 sites in Sweden
- Volunteers
- 167 people
- Sponsor
- Uppsala University Hospital
Advanced Cancer, Metastatic Cancer
Personalized Vaccine Generated by Autologous Dendritic Cells Pulsed With Autologous Whole Tumor Cell Lysate Treat Advanced Solid Tumor Patients With High Tumor Mutation Burden
The study is to investigate the safety and efficacy of dendritic cells vaccines pulsed with autologous whole tumor cell lysate for treating advanced solid tumor patients with high tumor mutation burden.
- Trial name
- NCT03671720
- Testing
- personalized DC vaccine
- Where
- China
- Sponsor
- Capital Medical University
Non-Small Cell Lung Cancer
Multicenter Observational Study of Advanced Non-small Cell Lung Cancer With Malignant Pleural Effusion
Multicenter observational study for correlation between tumor mutation burden and immunotherapy efficacy of advanced non-small cell lung cancer with malignant pleural effusion
- Trial name
- NCT04263688
- Testing
- Non-Intervention
- Volunteers
- 300 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 28 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Lung Neoplasm Malignant
Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]
This is single arm, prospective, multi-center, cohort study to evaluate blood TMB for improved efficacy of atezolizumab in locally advanced or metastatic NSCLC at the study enrollment who failed one or more prior lines of…
- Trial name
- BUDDY (NCT04059887)
- Testing
- Atezolizumab Injection [Tecentriq]
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Chonnam National University Hospital
Malignant Hydrothorax, NSCLC
A Prospective Study to Evaluate the Consistency of Next-Generation Sequencing(NGS)-Panels by Using Malignant Hydrothorax Form NSCLC
A prospective study to evaluate consistency of different NGS-panel. Cell free DNA is purified from each malignant hydrothorax from NSCLC .Different NGS-panels are applied to perform in vitro diagnosis to detect Single Nucleotide…
- Trial name
- NCT03546452
- Testing
- in vitro NGS-panel
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Mitochondrial Myopathies
mtDNA Mutation Load Analysis in Mesoangioblasts
Mitochondrial diseases caused by defects in oxidative phosphorylation (OXPHOS) due to heteroplasmic mitochondrial DNA (mtDNA) mutations are rare (frequency 1/5,000), but severe multi-system disorders.
- Trial name
- MABS05 (NCT05199740)
- Testing
- in vitro analysis
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Maastricht University
Myeloproliferative Neoplasm, Essential Thrombocythemia
Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)
Prospective study to evaluate the relevance of CALR allele burden monitoring as a molecular marker of disease progression.
- Conditions
- Myeloproliferative Neoplasm, Essential Thrombocythemia, Primary Myelofibrosis, Prefibrotic Stage, Primary Myelofibrosis, Fibrotic Stage
- Trial name
- CALRSUIVI (NCT04942080)
- Testing
- CALR allele burden quantification
- Where
- 10 sites in France
- Volunteers
- 260 people
- Sponsor
- University Hospital, Angers
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
This is an open-label, prospective, randomized, multicenter phase II trial that will evaluate the efficacy and safety of intermittent addition of cetuximab to a FOLFIRI-based first line therapy to patients with RAS (Rat…
- Trial name
- NCT04554836
- Testing
- Cetuximab, FOLFIRI
- Where
- 4 sites in Germany
- Volunteers
- 6 people
- Sponsor
- TheraOp
Chronic Myeloid Leukemia
French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients
A retrospective multi-center cohort study design was used to address the study objectives, using medical records obtained from three clinical centers in France.
- Trial name
- NCT05619978
- Testing
- 3L Therapy, T315I
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Myeloproliferative Neoplasm
Carotid Plaque Burden in Patients With Philadelphia Negative Myeloproliferative Neoplasms
In around 90% of the patients with MPNs, an acquired mutation that promotes JAK/STAT signaling is identified [3, 4]. The JAK/STAT pathway transduces signals from cytokines including erythropoietin, thrombopoietin, and granulocyte…
- Trial name
- NCT05993052
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Adenocarcinoma of the Colon
NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer
Colorectal cancer (CRC) is the 2nd to 3rd most common malignant disease in developed countries, with over 1 million new cases and 500,000 deaths worldwide each year.
- Trial name
- NEOPRISM-CRC (NCT05197322)
- Testing
- Pembrolizumab
- Where
- 6 sites in United Kingdom
- Volunteers
- 88 people
- Sponsor
- University College, London